Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 11 - 20 of about 174   

Articles published

GSK 1,330.94 -11.06 (-0.82%)
price chart
GlaxoSmithKline plc (GSK) Posts Quarterly Earnings Results, Beats Estimates ...
GlaxoSmithKline plc logo GlaxoSmithKline plc (NYSE:GSK) posted its quarterly earnings results on Wednesday. The company reported $0.90 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.79 by $0.11, AnalystRatings.
A Blue-Chip Starter Portfolio: GlaxoSmithKline plc, BHP Billiton plc And Rolls ...
Every quarter I take a look at the largest FTSE 100 companies in each of the index's 10 industries to see how they shape up as a potential 'starter' portfolio.
Traders Recap -GlaxoSmithKline plc (ADR)(NYSE:GSK), Dollar Tree, Inc ...  Techsonian (press release)
Related articles »  
Can GlaxoSmithKline plc Help You To Retire Rich?
It's been a very tough year for investors in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US). Shares in the pharmaceutical company have fallen by 10% over the last year and have shown little sign of improving their performance in recent weeks.
GlaxoSmithKline plc Receives "A+" Credit Rating (GSK)  Ticker Report
Related articles »  
Can Dividend Stock GlaxoSmithKline plc Bounce Back?
Given the widespread nature of this problem, Western authorities have taken a keen interest in the activities of their biopharmaceutical companies both abroad and at home.
Related articles »  
GSK Q3 Earnings Preview: Another Disappointing Quarter Ahead
GlaxoSmithKline plc (ADR) (GSK) will announce its financials for the third quarter of fiscal year 2014 (3QFY14) on Wednesday, October 22 before markets open.
GlaxoSmithKline plc Price Target Lowered to GBX 1425 at Panmure Gordon (GSK)
GlaxoSmithKline plc logo Investment analysts at Panmure Gordon lowered their price objective on shares of GlaxoSmithKline plc (LON:GSK) from GBX 1,600 ($25.75) to GBX 1,425 ($22.93) in a note issued to investors on Wednesday. The firm currently has a ...
Why GlaxoSmithKline plc Has Further To Fall
Investors in pharmaceutical giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have taken a beating lately. At 1450p, the stock is 15% off its 52-week high of 1706p.
China's decision to impose a record fine on GlaxoSmithKline Plc...  Mynextfone
GlaxoSmithKline plc (ADR) (NYSE:GSK) Nearly Half a Billion Dollars Fine ...  SmallCap Network
Related articles »  
3 Reasons Why GlaxoSmithKline plc Could Be Ripe For Takeover
Life as an investor in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) is tough at the moment. That's because shares in the pharmaceutical major have fallen by 10% in the last three months alone.
GlaxoSmithKline plc's Hold Rating Reaffirmed at Deutsche Bank (GSK)  WKRB News
Related articles »  
GlaxoSmithKline plc Is Still A Better Pick Than AstraZeneca plc
AstraZeneca It has been a terrible year for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and more bad news could be around the corner.
GlaxoSmithKline Needs Healthy Doses Of Good News Post China Scandal  Seeking Alpha (registration)
Related articles »  
GlaxoSmithKline plc (GSK) � Research Analysts' Recent Ratings Updates
GlaxoSmithKline plc had its �underperform� rating reaffirmed by analysts at Zacks. They now have a $40.00 price target on the stock.